Diabetes Technology and Therapeutics, 17, S131-S133. Mary Ann Liebert Inc. 'T Hart, L M, Fritsche, A, Nijpels, G, Van Leeuwen, N, Donnelly, L A, Dekker, J M, Alssema, M, Fadista, J, Carlotti, F, Gjesing, A P, Palmer, C N, Van Haeften, T W, Herzberg-Schäfer, S A, Simonis-Bik, A M, Houwing-Duistermaat, J J, Helmer, Q, Deelen, J, Guigas, B, Hansen, T, MacHicao, F, Willemsen, G, Heine, R J, Kramer, M H, Holst, J J, De Koning, E J, Häring, H U, Pedersen, O, Groop, L, De Geus, E J, Slagboom, P E, Boomsma, D I, Eekhoff, E M, Pearson, E R & Diamant, M 2015, ' In vivo efficacy of HD0471953 : A novel GPR119 agonist for the treatment of type 2 diabetes mellitus ', Diabetes Technology and Therapeutics, vol. 17, pp. S131-S133 . https://doi.org/10.1089/dia.2015.1514